China Resources Pharmaceutical Group Limited (FRA:640)
Germany flag Germany · Delayed Price · Currency is EUR
0.5350
+0.0050 (0.94%)
At close: Apr 17, 2025, 10:00 PM CET

FRA:640 Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
3,5264,4533,7334,7652,5152,636
Upgrade
Market Cap Growth
19.30%19.30%-21.66%89.46%-4.61%-49.28%
Upgrade
Enterprise Value
15,88216,72414,55015,34411,7569,818
Upgrade
Last Close Price
0.550.680.550.700.330.35
Upgrade
PE Ratio
8.0010.107.5910.034.826.39
Upgrade
PS Ratio
0.100.130.120.160.080.11
Upgrade
PB Ratio
0.270.340.320.440.190.26
Upgrade
P/TBV Ratio
1.531.941.632.090.981.07
Upgrade
P/FCF Ratio
--2.254.111.743.22
Upgrade
P/OCF Ratio
--1.883.251.422.57
Upgrade
EV/Sales Ratio
0.510.490.470.520.360.39
Upgrade
EV/EBITDA Ratio
8.848.708.409.687.117.08
Upgrade
EV/EBIT Ratio
10.6610.5510.3311.618.638.40
Upgrade
EV/FCF Ratio
--8.7513.248.1511.99
Upgrade
Debt / Equity Ratio
0.700.700.670.700.720.69
Upgrade
Debt / EBITDA Ratio
4.754.754.384.595.374.69
Upgrade
Debt / FCF Ratio
--4.776.616.528.44
Upgrade
Asset Turnover
1.021.021.061.001.031.00
Upgrade
Inventory Turnover
6.306.307.076.997.427.17
Upgrade
Quick Ratio
0.820.821.000.940.950.92
Upgrade
Current Ratio
1.411.411.331.251.251.20
Upgrade
Return on Equity (ROE)
8.80%8.80%8.96%8.09%7.60%7.12%
Upgrade
Return on Assets (ROA)
2.97%2.97%2.99%2.80%2.69%2.92%
Upgrade
Return on Capital (ROIC)
4.65%4.65%4.72%4.33%4.13%4.50%
Upgrade
Return on Capital Employed (ROCE)
9.50%9.50%9.80%10.40%9.20%10.80%
Upgrade
Earnings Yield
12.50%9.96%13.18%9.97%20.74%15.66%
Upgrade
FCF Yield
--44.53%24.32%57.39%31.05%
Upgrade
Dividend Yield
5.70%2.65%3.56%2.73%6.38%4.32%
Upgrade
Payout Ratio
--22.83%23.23%20.00%20.96%
Upgrade
Buyback Yield / Dilution
----0.01%0.02%
Upgrade
Total Shareholder Return
5.70%2.65%3.56%2.73%6.39%4.34%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.